89BIO INC. - COMMON STOCK

89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023

07 6 2023 08:00:01 提供 Nasdaq GlobeNewswire

89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

23 5 2023 08:00:01 提供 Nasdaq GlobeNewswire

89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

04 5 2023 16:05:00 提供 Nasdaq GlobeNewswire

89bio to Participate in Upcoming Investor Conferences

02 5 2023 08:00:01 提供 Nasdaq GlobeNewswire

89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock

24 3 2023 07:00:00 提供 Nasdaq GlobeNewswire

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

22 3 2023 16:16:12 提供 Nasdaq GlobeNewswire

89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks

22 3 2023 07:00:00 提供 Nasdaq GlobeNewswire

89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

10 3 2023 08:00:00 提供 Nasdaq GlobeNewswire

89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

04 3 2023 13:30:00 提供 Nasdaq GlobeNewswire

89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

21 2 2023 08:00:01 提供 Nasdaq GlobeNewswire

89bio to Participate in the SVB Securities Global Biopharma Conference

08 2 2023 08:00:02 提供 Nasdaq GlobeNewswire

89bio Provides Business Update and Outlook for 2023

04 1 2023 16:01:00 提供 Nasdaq GlobeNewswire

89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology

12 12 2022 18:30:00 提供 Nasdaq GlobeNewswire

89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

10 11 2022 16:05:01 提供 Nasdaq GlobeNewswire

89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022

05 11 2022 13:00:00 提供 Nasdaq GlobeNewswire

89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference

13 10 2022 08:00:01 提供 Nasdaq GlobeNewswire

89bio to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

07 9 2022 08:00:03 提供 Nasdaq GlobeNewswire

89bio Presents Positive Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at European Society of Cardiology Congress 2022

26 8 2022 06:00:00 提供 Nasdaq GlobeNewswire

89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2b Trial of Pegozafermin for the Treatment of NASH

18 8 2022 08:00:00 提供 Nasdaq GlobeNewswire

89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

11 8 2022 08:00:01 提供 Nasdaq GlobeNewswire